Alvotech (ALVO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.34B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IS | CEO | Lisa Graver |
| IPO Date | 2022-06-16 | CAGR | 62.44% |
| Employees | 1,279 | Website | www.alvotech.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $2.79B | P/E | -11.62 | Forward P/E | 15.89 | PEG | — |
| P/S | 7.38 | P/B | -15.48 | P/CF | -35.72 | P/FCF | -24.12 |
| Sales | $559.42M | Sales 1Y | -4.47% | Sales 3Y | 468.28% | Sales 5Y | 993.9% |
| EPS | $-0.34 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -36.37% | EPS QoQ | -100.72% | Sales QoQ Avg | 1.47% | EPS QoQ Avg | 520.43% |
| Gross Margin | 61.35% | Operating Margin | 13.8% | Profit Margin | -14.43% | ROCE | 6.65% |
| ROA | -6% | ROE | 35% | Altman Z Score | -1.45 | Piotroski Score | 2 |
| Current Ratio | 1.76 | Quick Ratio | 0.88 | Cash Ratio | 0.25 | Op. CF Ratio | -0.23 |
| Debt/Equity | -5.16 | Debt/Assets | 1.03 | Lt Debt/Equity | -4.96 | Lt Debt/Cap. | 1.29 |
| Intrst Cov. | 0.5 | Inventory Turnover | 0.95 | Asset Turnover | 0.39 | Receivables Turnover | 5.23 |
| Enterprise Value | $2.79B | P/E Ratio | -11.62 |
| Forward P/E | 15.89 | PEG Ratio | — |
| P/S Ratio | 7.38 | P/B Ratio | -15.48 |
| P/CF Ratio | -35.72 | P/FCF Ratio | -24.12 |
| EPS | $-0.34 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -4.47% | Gross Margin | 0.61% |
| Operating Margin | 0.14% | Profit Margin | -0.14% |
| ROE | 0.35% | ROA | -0.06% |
| ROCE | 0.07% | Current Ratio | 1.76 |
| Quick Ratio | 0.88 | Cash Ratio | 0.25 |
| Debt/Equity | -5.16 | Interest Coverage | 0.5 |
| Altman Z Score | -1.45 | Piotroski Score | 2 |
Alvotech (ALVO) valuation & financials
Alvotech (ALVO) has a market capitalization of $1.34B and trades at a price-to-earnings ratio of -11.6. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Alvotech's revenue grew -4.5% over the last year.
Alvotech's next earnings report is scheduled for August 19, 2026; analysts estimate EPS of $-0.06. Check the earnings calendar to see all companies reporting this week.
Alvotech (ALVO) — frequently asked questions
When does Alvotech (ALVO) report earnings next?
Alvotech is expected to report earnings on August 19, 2026. Analysts estimate EPS of $-0.06.
What is Alvotech's market cap?
Alvotech (ALVO) has a market capitalization of $1.34B.
What is ALVO's P/E ratio?
Alvotech trades at a price-to-earnings ratio of -11.6, with trailing twelve-month EPS of $-0.34.
How fast is Alvotech growing?
Alvotech's revenue grew -4.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)